Supplement spend, switching behavior, and willingness-to-pay among GLP-1 patients.
Structural demand signal: 98.6% of GLP-1 users fall below the dietary reference intake for both vitamin D and potassium — yet only 20% are referred to a registered dietitian, and 60% report inadequate nutritional guidance from their prescribing provider.[6][2] The supplement market for this population is not discretionary; it fills a clinical void left by standard prescribing practice.
Australia's GLP-1 market grew nearly 10-fold between May 2020 and April 2025, reaching 496,875 monthly units — with 47.8% of all GLP-1 receptor agonist users accessing privately (180,000–240,000 people per month) at costs of AUD $345–$645/month for weight management indications with no PBS subsidy.[22][10] New Zealand approved Wegovy for weight loss in March 2025 at NZD $430–$900/month (no Pharmac funding), with Australia's GLP-1 RA market projected to grow from USD $499 million (2024) to USD $1.9 billion by 2034 at a 14.3% CAGR.[22] This is a high-motivation, high-cost-burden cohort: self-funded patients spending up to AUD $5,000/year on medication carry strong financial and psychological incentive to maximize therapeutic outcomes through every available means, including supplementation.
Supplement purchasing among GLP-1 users is near-universal in the side-effect cohort: 85% of users who experience side effects actively purchase products to manage symptoms or address nutrition gaps, with approximately one-third each buying protein shakes, protein powders, and protein bars.[7] The unconditional overall adoption rate remains unquantified, but behavioral proxies converge on a high majority: 59–69% of Gen Z and Millennial GLP-1 users purchase vitamins and supplements; GLP-1 households outspend matched non-GLP-1 households by +22% on protein-enriched products and +38% on fresh vegetables, while cutting traditional snack spending by 31%.[7][21][24] Among weight-loss GLP-1 users tracked by Numerator (n=30,000), year-over-year supplement spend increased +58% on superfoods, +38% on protein shakes, and +23% on bone health products.[1]
The clinical driver of this demand is severe and consistent across nutrients. A 2025 cross-sectional study (Frontiers in Nutrition, n=69) found 98.6% of GLP-1 users below DRI for vitamin D (mean intake: 4 mcg vs. 20 mcg target) and potassium (2,186 mg vs. 4,700 mg target); 94.2% below for choline; 89.9% below for magnesium; and 88.4% below for iron.[6] Protein intake compounds the problem: only 43% of GLP-1 users meet the minimum 1.2 g/kg/day for muscle preservation, and only 10% reach the functional optimum of 1.6 g/kg/day — while 25–40% of total weight lost on GLP-1s is lean muscle mass, not fat.[6][5] GLP-1 use reduces caloric intake by 16–39%, creating what dietitian Devon Golem calls a state where "99% of GLP-1 users are falling short on vitamin D and potassium intake."[14] A Clinical Obesity narrative review found 12.7% of GLP-1 users develop new nutritional deficiencies within 6 months, including vitamin D (7.5%), iron (1.6%), and thiamine.[5]
Product attribute preferences among GLP-1 supplement shoppers converge tightly: 75% prioritize vitamin/nutrient fortification, 74% prioritize high protein, and 73% prioritize gut health support — three attributes that point to a single product archetype rather than a fragmented multi-SKU stack.[7] Only ~1% of global products currently combine both high protein and high fiber claims, confirming the formulation gap is real and the market position is open.[5] Side effects directly activate specific supplement categories: nausea (~50–54% prevalence) drives digestive and anti-nausea products; diarrhea (~28–33%) drives probiotics and electrolytes; fatigue (30%) drives iron, B12, and magnesium; and widely reported hair loss and "Ozempic face" drive biotin, collagen, and hyaluronic acid demand.[5][6]
Willingness to pay for targeted GLP-1 formulations is substantially above general supplement norms. ADM proprietary research found 83% of GLP-1 users interested in customized solutions and 80% willing to pay a premium for targeted products, with observed premiums of 25–45% above comparable conventional products.[33][2] Morning Consult (n=58,008 US adults) measured GLP-1 users at +6 pp quality premium, +12 pp convenience premium, and +8 pp sustainability premium versus non-users.[36] Active users already spend $95–$130/month on specialized GLP-1-compatible products, with precision nutrition subscription bundles reaching $150–$300/month.[2][25] In AU/NZ, the high out-of-pocket drug cost (up to AUD $5,000/year) compresses available supplement budget, and 74% of Australians cite rising living costs as a major concern — meaning price sensitivity is meaningfully higher than US data implies, even among self-funding GLP-1 users.[34][10]
Category dynamics show a decisive structural shift already underway. The traditional weight-management supplement category has collapsed: −22% YoY by NielsenIQ; −10.5% YoY for fat burners (SPINS); −54% for weight management supplements among GLP-1 users specifically.[21][23][37] GLP-1 companion categories are the inverse: digestive supplements +52%, beauty supplements +42%, blood sugar supplements +265%, and berberine ("nature's Ozempic") +5,617% in the natural channel — the latter driven almost entirely by a viral TikTok campaign.[23] In the AU/NZ market, proteins and amino acids are the fastest-growing supplement category at a 13.9% CAGR, directly aligned with GLP-1 muscle-preservation demand.[8] Weight management supplements now carry a 73% online sales share (up from 66% two years prior), with DTC powder subscriptions growing 18.2% in 2025.[23][2]
The GLP-1 supplement buyer has a distinctive psychographic profile — not simply an older chronic-disease patient. Morning Consult data (n=58,008) shows weight-loss GLP-1 users skew Gen X (35%) and Millennial (31%), urban (41% vs. 28% general population), affluent (31% earn $100K+ vs. 14% general), highly educated (27% with master's degree vs. 12%), and are early adopters (+15 pp) and trend followers (+15 pp).[36] The most important channel insight: GLP-1 users over-index on TikTok by +32 percentage points (68% vs. 36%), Reddit by +22 pp, and Instagram by +21 pp; 40% use social media as their primary health information source (61% of Gen Z).[36][7] Meanwhile, 80% conduct active product research before purchase and only 37% consult a medical professional — confirming that DTC content and community, not clinical referral, is the primary discovery channel.[7] In AU/NZ, the base is already supplement-habituated: over 50% of New Zealanders take supplements daily and 68% of Australians are actively seeking dietary improvements, meaning a GLP-1-targeted product layers onto existing behavior rather than requiring category creation.[9][8]
Discontinuation rates create a permanent cycling market that rivals the active-user opportunity. 75–90% of GLP-1 users eventually discontinue, with the KFF Health Tracking Poll at 75% and Acosta Group at 90% before one year; clinical records from Australia (MJA, n=1,911) show only 19% persistence at 12 months.[29][7][10] After stopping, weight regains at 0.4 kg/month — roughly 4× faster than diet or exercise approaches — and the regained weight carries a higher fat-to-muscle ratio than pre-treatment, sustaining protein and muscle-preserving supplement demand long after medication stops.[5][39] Critically, 76% of discontinuers maintain the same or lower food intake after stopping, and 46% say they would restart the drug if costs decreased or insurance covered it — a population primed for supplement retention as a bridge product.[7]
Subscription churn data reveals both the vulnerability and the lever. DTC supplement replenishment subscriptions average 7–10% monthly churn; over half of subscribers cancel within 6 months; 41% of consumers report subscription fatigue; price increases trigger a 15% immediate churn spike.[38][17] The highest-leverage retention mechanism is plan structure: annual plans reduce churn by 51% vs. monthly billing, and prepaid 3–6 month plans increase retention by 40%.[17][38] A pause option reduces cancellations by 18% — particularly relevant for GLP-1 users who cycle on and off medication and whose appetite variability creates delivery frequency mismatches with standard 30-day supply cycles.
Implications: The opportunity is structural, not trend-driven. GLP-1 users present documented, clinically quantified deficiencies (Vitamin D: 98.6% below DRI; protein: 57% below minimum threshold) with no systematic HCP solution — making the supplement case credible and evidence-based rather than aspirational. Product architecture should prioritize the trifecta of vitamins/minerals + protein + gut health in a single SKU, targeting the "all-in-one" preference expressed by Australian consumers. Pricing in AU/NZ must account for the significant drug cost burden already carried by these patients; a mid-premium position ($80–$120 AUD/month) with a clearly articulated value-per-dollar narrative will outperform a pure premium play. Retention strategy should default to annual plan offers at acquisition rather than monthly — the 51% churn reduction from annual plans dwarfs any other retention lever by a wide margin. Distribution should prioritize pharmacies (highest AU/NZ consumer trust channel) and online DTC simultaneously, with social content (TikTok, Instagram) as the primary discovery channel for the target Gen X/Millennial segment. The post-cessation cohort is too large to ignore: 76% of former GLP-1 users maintain dietary discipline after stopping, creating a natural re-engagement window that a well-timed lifecycle email or pause-to-resume subscription flow can capture.
GLP-1 drug adoption has reached mass-market scale in the US, with meaningful but smaller penetration in Australia and New Zealand. As of May 2024, 12% of U.S. adults have ever used a GLP-1 drug and 6% are currently active users, representing approximately 15 million people.[29] The Food Institute estimates 23% of U.S. households currently include a GLP-1 user, projected to rise to 35% by 2030.[32] By 2030, an estimated 30 million U.S. adults (9% of population) are expected to be on GLP-1 drugs for weight loss.[31][15]
Note: All prevalence data in this section is US-sourced unless explicitly flagged AU/NZ. See also: GLP-1 Adoption NZ/AU.
| Population Group | % Who Have Used GLP-1s |
|---|---|
| Adults diagnosed with diabetes[29] | 43% |
| Adults with heart disease[29] | 26% |
| Adults told by doctor they are overweight/obese[29] | 22% |
| Adults aged 50–64[29] | 19% (peak age bracket) |
| Black adults[29] | 18% |
| Hispanic adults[29] | 13% |
| White adults[29] | 10% |
| Adults aged 65+[29] | Low; only 1% for weight loss alone |
| Indication | Share of GLP-1 Users |
|---|---|
| Chronic condition treatment (total)[29] | 62% |
| Chronic condition only (diabetes/heart)[29] | 39% |
| Both chronic condition and weight loss[29] | 23% |
| Weight loss exclusively[29] | 38% |
79% of users obtained GLP-1 prescriptions via primary care doctor or specialist; 11% from online/telehealth providers; 10% from medical spas or aesthetic centers — indicating a meaningful DTC/telehealth channel presence.[29]
| Metric | Australia | New Zealand |
|---|---|---|
| Adult population currently using GLP-1s[22][39][10] | ~2% (~500,000 adults) | No separate figure; following AU trajectory |
| Monthly units sold (Apr 2025)[22] | 496,875 units | — |
| Growth in monthly units (May 2020→Apr 2025)[22] | ~10× (57,941 → 496,875) | — |
| Private market access share[22] | 47.8% of all GLP-1 RAs (180K–240K people/month) | 100% private (no Pharmac funding for weight loss) |
| Weight loss GLP-1 approval date[26] | Wegovy: Sep 2024; Mounjaro: Sep 2024 | March 2025 |
| Product mix (AU, 2024–25)[22] | Semaglutide 63.3%; Tirzepatide 30.7% | — |
Key finding: Australia's GLP-1 market grew nearly 10-fold in five years, reaching ~500,000 monthly users with 47.8% accessing privately — representing a large, self-funding consumer base with strong incentive to optimize outcomes through supplementation.[22]
[US DATA — AU/NZ behavioral equivalents flagged where available]
GLP-1 use fundamentally restructures supplement purchasing. 85% of GLP-1 users who experience side effects purchase products to manage symptoms or address nutrition gaps.[7] NutraIngredients, citing Acosta data, reports approximately one-third of GLP-1 users purchase protein shakes (~30%), protein powders (~30%), and protein bars (~29%); these specific figures are not present in Acosta's public release.[5]
Overall supplement adoption among GLP-1 users: No single survey provides an unconditional adoption rate across all GLP-1 user types. The available proxies are: 59–69% of Gen Z and Millennial GLP-1 users purchase vitamins/supplements (Acosta Group)[7][19]; and the 85% figure cited above is conditional on experiencing side effects. Taken together, these proxies suggest a substantial majority of GLP-1 users engage with the supplement category in some form, but the unconditional overall rate remains unquantified in the corpus.
| Behavior | GLP-1 Households vs. Matched Non-Users |
|---|---|
| Likelihood of seeking low-calorie or energy-boost labels[21] | 1.5x as likely |
| Likelihood of shopping Online Grocery and Club channels[21] | 1.5x as likely |
| Overall spend (13-week period vs. prior year)[24] | +22% |
| Supplement Category | YoY Spend Change (GLP-1 Weight-Loss Users) |
|---|---|
| Superfoods[1] | +58% |
| Protein shakes[1] | +38% |
| Bone health products[1] | +23% |
| Digestive health[1] | +6% |
| Generation | Vitamins/Supplements | Energy Drinks/Powders | Purchase Channel |
|---|---|---|---|
| Gen Z[7][19] | 59% | 55% | 50/50 online vs. in-store |
| Millennials[7][19] | 69% | 39% | 50/50 online vs. in-store |
50–60% of GLP-1 users have switched their primary grocery retailer since starting the drug, seeking stores that offer enhanced health and wellness information (Kantar Retail IQ, reported via New Hope Network).[31] Simultaneously, iHerb created a dedicated "GLP-1 Support" category stocking nearly 4,700 products, and Amazon launched a "GLP-1 Support Nutrition" storefront with 500+ curated SKUs.[30][21]
Following the GLP-1 adoption surge, GNC's weight management category attracted the highest number of new customers seen in several years, driving a 30%+ increase in sales. Supergut sales grew approximately 4× from end of 2023 to mid-2024.[31]
The pillar scope asks why GLP-1 users switch supplement brands. The corpus does not contain a quantified survey on supplement brand-level switching drivers — this is a research data gap. The closest behavioral proxy is retailer switching: 50–60% of GLP-1 users have switched their primary grocery retailer since starting the drug, seeking stores with stronger health and wellness offerings (Kantar Retail IQ, reported via New Hope Network).[31] The retailer-switching figure (50–60%) serves as the best available proxy for category-level brand openness; specific supplement brand switching rates and drivers would require dedicated consumer panel data not present in the current corpus.
GLP-1 users (US-derived PwC GLP-1 Trends & Impact Survey, n≈3,000) report cutting food purchases by ~11%, particularly indulgent categories (high-calorie snacks, alcohol); equivalent AU/NZ panel-level data is not present in the corpus, and this figure should be treated as a cross-region proxy. Electrolyte supplements, hair-growth products, and anti-nausea medications are spiking among AU/NZ GLP-1 users.[22]
Key finding: 85% of GLP-1 side-effect-experiencing users actively purchase products to manage symptoms or nutritional gaps, creating a near-universal supplementation market among this cohort.[7]
| Attribute | % of GLP-1 Shoppers Prioritizing |
|---|---|
| Products fortified with vitamins/nutrients[7] | 75% |
| High protein or protein-fortified[7] | 74% |
| Gut health support[7] | 73% |
Additional prioritized attributes include brain health, muscle health support, microbiome benefits, sugar-conscious formulations, carbohydrate-free options, and low sodium.[19][24]
| Category | Primary Driver | Key Products |
|---|---|---|
| High-protein formulations[12][5] | Muscle preservation (25–39% of weight lost is muscle) | Protein shakes, powders, bars, BCAAs, creatine |
| Fiber/prebiotic products[12][33] | GI side effects, satiety | Prebiotic fibers, digestive enzymes |
| Micronutrient formulations[14][5] | Deficiency from caloric restriction | Vitamin D, potassium, magnesium, choline, iron |
| Bone health[33][31] | Calcium depletion | Calcium, vitamin D, vitamin K |
| Hydration/electrolytes[31][5] | Dehydration, cramps from GI effects | Electrolyte powders, drinks |
| Beauty supplements[23][33] | "Ozempic face," hair loss | Collagen, biotin, hyaluronic acid |
Popular ingredients among supplement-seeking consumers who want natural GLP-1 alternatives: berberine, chromium, Ceylon cinnamon, vitamin B1, Gymnema sylvestre, probiotics, digestive enzymes, fiber.[31] Only ~1% of global products currently combine both high protein AND high fiber claims — representing a formulation gap aligned with GLP-1 users' dual needs.[5]
Key finding: The top three attributes GLP-1 shoppers prioritize — vitamins/nutrients (75%), high protein (74%), and gut health (73%) — converge on a single product archetype: a comprehensive GLP-1 companion supplement addressing deficiency, muscle preservation, and GI tolerance simultaneously.[7]
The strongest peer-reviewed evidence on GLP-1 supplement demand drivers comes from a 2025 cross-sectional study (n=69, Frontiers in Nutrition), which quantified deficiency rates across key micronutrients in active GLP-1 users.[6][16][35]
| Nutrient | Mean Daily Intake | DRI Target | % Below DRI |
|---|---|---|---|
| Vitamin D[6] | 4 mcg | 20 mcg | 98.6% |
| Potassium[6] | 2,186 mg | 4,700 mg | 98.6% |
| Choline[6] | 305 mg | 550 mg | 94.2% |
| Magnesium[6] | 266 mg | 420 mg | 89.9% |
| Iron[6] | 12.1 mg | 18 mg | 88.4% |
| Calcium[6] | 863 mg | 1,300 mg | Significant deficit† |
| Fiber[6] | 14.5 g | 28 g | Below national average† |
| Vitamin A[6] | 560 mcg | 900 mcg | Below DRI |
| Vitamin C[6] | 51 mg | 90 mg | Below DRI |
| Vitamin E[6] | 9.6 mg | 15 mg | Below DRI |
Sample: 69 US participants, 82.6% White/Caucasian, mean age 49.6 years, 53.6% on semaglutide. Results may not fully generalize to AU/NZ populations.
† Frontiers in Nutrition 2025 study did not report exact percentages below DRI for calcium and fiber; qualitative descriptions retained from source.
Registered dietitian Devon Golem summarizes: "99% of GLP-1 users are falling short on vitamin D and potassium intake."[32] GNC research confirms GLP-1 users consistently lack calcium, iron, magnesium, potassium, choline, vitamins A, C, D, E, K, fiber, and protein.[32] An independent Clinical Obesity narrative review found 12.7% of GLP-1 users develop new nutritional deficiencies at 6 months, including vitamin D (7.5%), iron (1.6%), and thiamine (0.02%), with rates increasing at 12 months.[5]
| Metric | Value |
|---|---|
| Users meeting ≥1.2 g/kg bodyweight (minimum for muscle preservation)[6][5] | 43% |
| Users reaching 1.6 g/kg (functional optimum)[6] | 10% |
| Users reaching 2.0 g/kg (maximum benefit)[6] | 5% |
| Actual mean protein intake[6] | ~77.3 g/day |
| Protein needed for muscle preservation at median body weight[6] | ~120 g/day |
| % of total weight lost that is muscle mass (36–72 weeks)[6][5][4] | 25–39% (up to 40% per Food Institute)[32] |
While protein as a percentage of calories appeared adequate at 18.5%, absolute protein intake is critically insufficient for the body weights involved. This gap is the primary clinical driver of protein supplement demand in GLP-1 users.[6]
GLP-1 usage reduces daily calorie intake by 16–39%. GLP-1 users eat roughly 20% less food overall, yet protein and micronutrient intake frequently falls short of minimum recommendations despite this dietary shift.[12][32]
| Side Effect | Prevalence[5][6] | Supplement Category Activated |
|---|---|---|
| Nausea | ~50–53.7% | Anti-nausea, digestive health, ginger supplements |
| Diarrhea | ~27.8–33% | Probiotic/prebiotic, electrolytes |
| Vomiting | ~20% | Electrolytes, B vitamins |
| Fatigue | 30.3% | Iron, B12, magnesium |
| Muscle loss | 25–40% of weight lost | Protein, creatine, BCAAs |
| Hair loss (telogen effluvium) | Reported widely[31][33] | Biotin, collagen |
| Facial fat loss ("Ozempic face") | Reported widely[31][33] | Collagen, hyaluronic acid, beauty supplements |
| Dehydration/cramps | Reported[31] | Electrolyte supplements |
AU-specific note: Commonly reported Australian side effects include nausea, vomiting, diarrhoea, abdominal pain, and muscle mass loss. Post-medication patients who regain weight do so with a higher fat percentage than pre-treatment — creating sustained, long-term supplement demand.[39]
Key finding: 98.6% of GLP-1 users fall below DRI for both vitamin D and potassium — yet only 20% are referred to a registered dietitian. This clinical gap creates the structural demand for supplementation.[6][2]
The absence of structured nutritional support in GLP-1 clinical practice is the primary structural driver of the self-directed supplement market. Data from the Frontiers in Nutrition 2025 study and multiple industry surveys consistently identify an information void that DTC supplement brands are positioned to fill.
| Support Metric | Rate |
|---|---|
| GLP-1 patients receiving information on managing potential side effects[6] | 51% |
| Patients referred to a registered dietitian nutritionist[6] | 20% |
| Patients reporting insufficient nutritional guidance from HCPs[2][14][32] | 60% |
No structured evidence-based clinical or patient education pipeline exists for GLP-1 treatments in Australia — creating an opportunity for supplement brands to fill the information void responsibly.[22][10]
Key finding: Only 20% of GLP-1 patients are referred to a dietitian, yet 60% report inadequate nutritional guidance — creating a structural demand for DTC brands that provide education alongside supplementation.[6][2]See also: Clinical Evidence
| Research Source | Sample | Finding |
|---|---|---|
| ADM Proprietary Research[33] | GLP-1 therapy users | 83% interested in customized GLP-1 solutions; 80% willing to pay a premium for targeted products |
| Future Market Insights / FinanceBuzz / IFT[2][25][33] | US GLP-1 users | Willing to pay 25–45% premiums above conventional comparable products |
| Morning Consult[36] | 58,008 US adults | GLP-1 users +6 pp quality premium; +12 pp convenience premium; +8 pp sustainability premium vs. non-users |
| ScienceDirect / FinanceBuzz[25] | US retail | GLP-1 use makes own-price elasticities for protein products up to 0.22 more inelastic (less price-sensitive) |
| Product Type | Monthly Spend per Person (USD) |
|---|---|
| Specialized GLP-1-compatible food + supplement products[2][33] | $95–$130 |
| Demographic Metric | GLP-1 Users | General US Population |
|---|---|---|
| Household income $100K+[36][33] | 31% | 14% |
| Master's degree or higher[36][33] | 27% | 12% |
| Investment portfolio $50K+[36] | 42% | 25% |
| Have health insurance[36] | 96% | 86% |
74% of Australians identify rising living costs as a major concern and 55% feel financially insecure — suggesting AU/NZ consumers may be more price-sensitive than US data implies, even among the affluent GLP-1 segment.[34] GLP-1 drugs themselves cost AU$345–$645/month (tirzepatide)[39] and NZ$430–$900/month (Mounjaro)[26] with no public subsidy for weight loss — the out-of-pocket GLP-1 cost burden alone shapes what is left for supplement spend.
Key finding: 80% of GLP-1 users are willing to pay a premium for targeted formulations, and active users already spend $95–$130/month on GLP-1-compatible products — but in AU/NZ, drug costs of up to $645/month (AUD) likely compress available supplement budget compared to the US.[33][39]
| Supplement Category | Change vs. Pre-GLP-1 Baseline |
|---|---|
| Blood sugar/diabetic supplements[23] | +265% |
| Digestive supplements[23] | +52% |
| Beauty supplements[23] | +42% |
| Weight management supplements[23] | −54% |
| Ingredient/Category | YoY Growth |
|---|---|
| Barberry (berberine) — "nature's GLP-1"[23] | +5,617% |
| Collagen[23] | +126% |
| Chromium[23] | +77.5% |
| Green tea[23] | +14% |
| Berberine (SPINS year to Oct 6, 2024)[37][4] | +21.6% YoY |
| Green supplements[37] | +16.3% YoY |
| Protein products (52-week period ending Nov 5, 2023)[31] | +15% |
| Blood sugar support at The Vitamin Shoppe (2023)[31] | +40%; Advanced Blood Sugar +70% in Q1 2024 |
| Channel / Metric | Dollar Change | Unit Change |
|---|---|---|
| Combined mainstream + natural channel (Aug 2024 → Aug 2025)[23] | −3% ($156.4M → $152M) | −12% YoY |
| Amazon weight management[23] | −14% ($216.5M → $186.8M) | −16% YoY |
| NielsenIQ overall weight management[21] | −22% YoY; −29% vs. 2 years ago | — |
| Traditional weight management (fat burners): SPINS[37][4] | −10.5% YoY | — |
| Probiotic supplements[37] | −7.6% YoY | — |
| Multivitamins[37] | −2.7% YoY (improving vs. prior year's −7%) | — |
| Contrast: Overall dietary supplement sales[21] | +17% YoY; +32% vs. 2 years ago | — |
Weight management supplements now carry a 73% online sales share (up from 66% two years ago), exceeding the 62% online average for all supplements.[23] DTC subscriptions for powder-based supplements grew +18.2% in 2025.[2]
Key finding: The traditional "weight loss pill" category has collapsed (−22% NielsenIQ; −10.5% SPINS fat burners) while GLP-1 companion categories surge — berberine +5,617%, digestive supplements +52%, beauty supplements +42%. The structural shift is irreversible as long as GLP-1 adoption continues.[23][37][21]See also: Competitive Landscape
| Metric | Value |
|---|---|
| Global GLP-1 nutritional support market (2025)[2][27] | USD $4.1 billion |
| Projected global market (2035)[2] | USD $13 billion (CAGR 12.2%) |
| Protein & macronutrient blends market share (2025)[2] | 43% |
| Powders market share (2025)[2] | 38% (up from 34.2% in 2024) |
| Prescription (Rx) channel share (2025)[2] | 72% (up from 68.5% in 2024) |
| Products with GLP-1-related claims — 5-year CAGR[12] | 124%; North America = 83% of growth |
| SKU growth in high-protein beverages/meal replacements targeting GLP-1 users[21] | +47% YoY since 2024 |
| Amazon functional ingredients with 20%+ growth (probiotics, taurine, yerba mate, L-carnitine)[23] | Multiple categories |
Key finding: Products making GLP-1-related claims grew at a 124% CAGR over five years, with North America comprising 83% of that growth — indicating the market is still in early expansion phase and non-US markets (including AU/NZ) represent untapped upside.[12]See also: Channel Economics
GLP-1 users are not monolithic. IFT Food Technology research identifies three distinct behavioral segments that require differentiated product and marketing strategies:[20][33]
| Segment | Behavior Pattern | Supplement Opportunity |
|---|---|---|
| Minimal lifestyle changers | Taking medication without behavioral shifts | Convenience-first; single-SKU comprehensive solutions |
| Comprehensive wellness adopters | 180° lifestyle changes: whole foods, supplements, exercise | High-engagement; premium, multi-SKU stacking |
| Moderate approach | Partial lifestyle changes; selective supplementation | Mid-tier; guidance-seeking; DTC education-led |
| Demographic | GLP-1 Users | General US Population |
|---|---|---|
| Gen X (primary age cohort)[36] | 35% | 25% |
| Millennials[36] | 31% | 28% |
| Married[36] | 57% | 41% |
| Have children at home[36] | 45% | 27% |
| Urban[36] | 41% | 28% |
| Earn $100K+[36][33] | 31% | 14% |
| Master's degree or higher[36] | 27% | 12% |
| $50K+ in investments[36] | 42% | 25% |
| Have health insurance[36] | 96% | 86% |
Future Market Insights confirms the primary age group for GLP-1 nutritional supplement products is 35–54 years (33% market share, 2025), with 56% of GLP-1 prescriptions written for this bracket.[2]
| Psychographic Trait | GLP-1 Users | General Population | Difference |
|---|---|---|---|
| Early adopters[36] | Over-index | Baseline | +15 pp |
| Trend followers[36] | Over-index | Baseline | +15 pp |
| Status-seeking[36] | Over-index | Baseline | +12 pp |
| Willing to pay for convenience[36] | Over-index | Baseline | +12 pp |
| Impulsive behavior[36] | 49% | 38% | +11 pp |
| Health-focused (primary food decision driver)[36] | 74% | 63% | +11 pp |
| Platform / Source | GLP-1 Users | General Population | Difference |
|---|---|---|---|
| TikTok usage[36] | 68% | 36% | +32 pp |
| Reddit[36] | Over-index | Baseline | +22 pp |
| Instagram[36] | Over-index | Baseline | +21 pp |
| LinkedIn[36] | Over-index | Baseline | +20 pp |
| Social media as primary health info source[7][36] | 40% (61% Gen Z) | — | — |
| Consult medical professionals for health research[7] | 37% | — | — |
| Consult nutritionists[7] | 36% | — | — |
| Conduct product/health research overall[7] | 80% | — | — |
The social media over-indexing has direct product implications: berberine became a mass-market phenomenon driven by a viral TikTok campaign dubbing it "nature's Ozempic."[31][4]
| Dimension | Diabetes-Only Users | Weight-Loss Users |
|---|---|---|
| Share of GLP-1 market[24] | 48% | 31% (19% dual-use) |
| Age profile[24] | Older | Younger, families with children |
| Income[24] | Lower (<$50K) | Higher ($150K+) |
| Overall retail spend[24] | Average | Above average ("valuable store shoppers overall") |
| Premium supplement WTP (Analysis: based on income and WTP data above) | Lower | Higher |
Key finding: GLP-1 weight-loss users — the primary supplement target — skew Gen X and Millennial, urban, affluent ($150K+), married-with-children, highly educated, and acutely social-media active (TikTok +32 pp). This profile aligns closely with DTC subscription brands' sweet spot.[36][24]
GLP-1 discontinuation rates are high and create a large, permanent cycling population with distinct supplement needs on both sides of the medication gap.
| Source | Discontinuation Metric | Rate |
|---|---|---|
| Acosta Group (4,489 US adults)[7] | % discontinued before 1 year | 90% |
| Acosta Group[7] | % current users expecting to discontinue within 2 years | 53% |
| MJA clinical records (n=1,911, 2015–2022)[10] | Persistence at 1 year | 19% (i.e., 81% discontinued) |
| New Hope Network[31] | Discontinued before clinically meaningful benefits | 58% of 170,000 patients |
| Reason | Data |
|---|---|
| Cost (primary driver)[5][29][7] | ~50% cite within first year; 54% US users report difficulty affording; 31% Acosta respondents cite cost; 22% say "very difficult" to afford |
| Side effects[7] | 76% of Acosta discontinuers cited side effects as a concern |
| Supply shortages[10] | Major issue in Australia (Ozempic shortages from late 2022) |
| Metric | Value |
|---|---|
| Average monthly weight regain[5][39] | 0.4 kg/month |
| Time to return to baseline weight[5] | ~2 years |
| Regain speed vs. diet/exercise approaches[5] | ~4× faster |
| Body composition of regained weight[5][39] | Higher fat : muscle ratio than pre-treatment — creates sustained protein/muscle-preserving supplement demand |
76% of GLP-1 users who discontinued continue eating the same or less food after stopping, maintaining healthier habits.[7] Post-medication grocery patterns normalize first; candy and baked goods rebound within 3–6 months; fresh produce and meat consumption remains elevated. 46% of former GLP-1 users say they would take the medication again for additional weight loss; 47% of Gen Z and Gen X would restart if costs decreased or insurance covered it.[7]
Hannah Ackermann (VP Marketing, COMET), quoted in IFT: "They've lost a lot of weight, they are super-motivated to keep it off, and they are willing to spend money on products that work for them. Having a product that helps with satiety or weight management while off the drug will be a big deal."[33]
The high discontinuation rate (58–90% depending on cohort and time horizon) creates a permanent cycling population — at any time, a large cohort is seeking natural supplements either as alternatives to medications they can no longer afford, or as transitional products when medications are paused.[31]
Key finding: With 90% of GLP-1 users in the Acosta cohort discontinuing before one year (n=4,489), and weight regaining at 4× the rate of diet/exercise approaches — the post-cessation segment represents a structurally large, permanently recurring market for weight management and muscle-preserving supplements.[7][5]
| Drug | Monthly Cost (AUD) |
|---|---|
| Tirzepatide (Mounjaro) — weight management[39] | $345–$645/month |
| Semaglutide (Wegovy) — weight management[10] | Up to $500/month; ~$300 compounded |
| Semaglutide (Ozempic) — PBS subsidised, diabetes only[10] | ~$42/month |
| Semaglutide — off-label obesity use[10] | ~$133/month |
| Annual cost (max private)[10][39] | Up to $5,000/year |
| Drug | Monthly Cost (NZD) |
|---|---|
| GLP-1 prescriptions (general)[26] | ~$500/month |
| Mounjaro (tirzepatide), dose-dependent[26] | $430–~$900/month |
| Milestone | Australia | New Zealand |
|---|---|---|
| Wegovy (semaglutide 2.4mg) weight management approval[39][22] | Sep 2024 | March 2025 |
| Mounjaro (tirzepatide) weight management approval[39][22] | Sep 2024 | Dec 2025 (Medsafe) |
| PBS/Pharmac subsidy for obesity | Not yet; Wegovy likely for CVD+obesity group soon[39] | None[26] |
| TGA ad removal (FY2024–25)[22][10] | 3,000+ weight-loss supplement ads removed | — |
Australia's GLP-1 RA market was valued at USD $499.12 million in 2024, projected to reach USD $1,899.62 million by 2034 (CAGR 14.30%).[22] Telehealth company Eucalyptus doubled annual revenue to ~$250 million driven primarily by GLP-1 demand.[22]
Māori and Pasifika communities have disproportionately high obesity and diabetes rates due to structural inequities, yet are least able to afford private GLP-1 prescriptions at NZ$430–$900/month — meaning GLP-1 drugs and associated premium supplements are effectively available only to higher-income consumers.[26]
TGA removed 3,000+ online ads for weight-loss therapeutic goods in FY2024–25.[22] Supplement companies making misleading claims of replicating GLP-1 effects face regulatory risk. Acceptable marketing language in regulated markets centers on "nutrient replenishment" and "dietary routine support" — explicit GLP-1 alternative or "faux-zempic" claims are prohibited.[5]
Key finding: Australian GLP-1 users pay up to AUD $5,000/year privately (no PBS obesity subsidy) while the market grew 10-fold in five years — creating a high-motivation, high-cost-burden cohort with strong incentive to maximize therapeutic outcomes via supplementation.[22][10]See also: GLP-1 Adoption NZ/AU
| Market Segment | 2024 Value | Forecast | CAGR |
|---|---|---|---|
| AU/NZ dietary supplements[8][18][34] | USD $3.60B | USD $6.55B (2030) | 10.6% |
| Broader AU/NZ nutraceuticals[18] | USD $11.51B | USD $26.10B (2033) | 9.5% |
| Liquid dietary supplements[18] | USD $167.4M | — | 12.9% |
| AU/NZ herbal supplements[34] | USD $1.4B (2025) | USD $2.2B (2032) | 7.4% |
| Demographic Metric | Data |
|---|---|
| Adults as share of end-use market (2024)[8] | 62.6% |
| Core consumer age segment[8] | 25–50 years |
| Australians actively seeking to improve well-being through dietary changes and supplements[8][18] | 68% |
| Higher supplement use among[8] | Females; older adults; higher education; lower socioeconomic disadvantage |
| NZ consumers taking supplements or natural remedies daily[9] | >50% (Consumer NZ survey) |
| NZ top supplements[9] | Vitamin C, magnesium, probiotics |
| Category | Market Share / Position (2024) | Growth Rate |
|---|---|---|
| Vitamins[8][34] | 29.4% — dominant category | High (vitamin C, D, multivitamins) |
| Proteins & Amino Acids[8][34] | — | Fastest-growing: 13.9% CAGR |
| Botanicals[8] | 32.8% of liquid supplements | Growing |
| Minerals (calcium, magnesium, iron, zinc)[8] | — | Growing |
| Bone & Joint Health[8] | Largest application segment | Aging population driver |
Proteins & amino acids at 13.9% CAGR directly align with GLP-1 muscle-preservation demand and represent the fastest-growing category in the AU/NZ market — a structural market fit for GLP-1 companion protein products.[8][34]
| Form | Position |
|---|---|
| Tablets[8] | 31.6% — largest share; preferred by older buyers for precise dosage |
| Powders[8] | Fastest-growing; preferred by younger consumers for customization |
| Gummies[8][9] | Growing segment; gaining popularity in NZ |
| Functional beverages[9] | +22% unit growth YoY (NZ data) |
| Channel | Position | Key Driver |
|---|---|---|
| Pharmacies & drug stores[8][18] | Largest distribution channel | Highest consumer trust; pharmacist interaction |
| Supermarkets & health food stores[8] | Significant offline channel | Convenience, habitual purchase |
| Online / DTC[8][18] | Fastest-growing channel | Internet penetration, subscription models |
New Zealand consumers demonstrate: strong preference for sustainable products; demand for brand transparency; loyalty to local brands; increasing skepticism toward premium pricing without clear benefits; focus on long-term health investment over quick fixes; preference for proactive/preventive health framing over reactive.[9]
Australian consumers show: growing demand for clean-label, organic, and plant-based supplements; younger urban consumers rely on digital platforms and fitness influencers; heightened interest in mental well-being, sleep quality, and digestive health; preference for "all-in-one" solutions over single-benefit supplements; flavor, dosage format, and ease of use are key purchase considerations.[8][34]
| Health Priority | % of Australians |
|---|---|
| Rate their health positively[34] | 80% |
| Intend to consume more fresh produce[34] | 50% |
| Aim to reduce alcohol intake[34] | 30% |
| Identify rising living costs as major concern[34] | 74% |
| Feel financially insecure[34] | 55% |
Adaptogens (Ashwagandha, Lion's Mane) trending for stress and cognitive support; gummy formats gaining popularity; "free-from" and "better for you" supermarket items expanding; three of four FMCG suppliers prioritizing health and wellness new product development.[9]
Swisse Wellness, Blackmores, FIT-BioCeuticals, Pharmacare Laboratories Australia, Sanderson Vitamins, Healtheries (Vitaco).[8]
Key finding: Over 50% of New Zealanders already take supplements daily, and 68% of Australians are actively seeking dietary improvements — the AU/NZ supplement market is a supplement-habituated population where a GLP-1-targeted product can layer onto existing purchase behavior rather than creating a new one.[9][8]See also: Competitive Landscape
Primary-source-confirmed figures from the cited Recurly and Recharge articles are limited; only the data points below survive direct verification against the public articles.[17][38]
| Metric | Value | Source |
|---|---|---|
| Annual cost to businesses of poor customer service[17] | >$75 billion (Havas, cited via Recurly) | Recurly |
| Brands at risk of disappearing without stronger customer experience[17] | ~75% (Havas, cited via Recurly) | Recurly |
| Cancellations saved via post-cancellation flow (Wildgrain case study)[38] | 22% | Recharge |
The GLP-1 supplement buyer profile creates unique churn dynamics not captured in standard DTC benchmarks:
AU/NZ context note: Baby Boomers — a primary AU/NZ GLP-1 supplement demographic — gravitate toward nutraceuticals over tech-heavy subscription management interfaces; subscription UX complexity may itself be a churn driver in this cohort.
Key finding: GLP-1 supplement users are already paying $345–$645/month for medication, creating high baseline cost-burden and elevated price sensitivity. Retention strategy for this cohort must prioritize value reinforcement and flexibility — pause, dose-cycle alignment, and post-cessation re-engagement — over generic loyalty mechanics. Primary-source-confirmed quantified levers from the cited corpus remain limited and are flagged above as a data gap.[39]See also: Channel Economics